CD47 and myelodysplastic syndrome: Researchers found that treatment with azacitidine leads to a 4- to 6-fold upregulation of CD47 expression in MDS cell lines (MOLM-13 and SKM-1), which may enhance the efficacy of anti-CD47 monoclonal antibodies [146].